CORMEDIX INC. Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
CORMEDIX INC. (CRMD) had Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price of $4.96 per share as of 2020-12-31, per its 10-K filed 2021-03-30.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 · last filed 2021-03-30
- 2020-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $4.96.
- 2020-03-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $8.28.
- 2019-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $6.24.
- 2018-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $5.50; Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price as first filed $1.10.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2020-12-31 | $4.96 10-K · filed 2021-03-30 | |
| 2020-03-31 | $8.28 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $6.24 10-K · filed 2021-03-30 | |
| 2018-12-31 | $5.50 10-K · filed 2020-03-16 | $1.10 10-K · filed 2019-05-29 |
| 2017-12-31 | $1.08 10-K · filed 2019-05-29 | |
| 2016-12-31 | $1.65 10-K · filed 2018-03-19 | |
| 2015-12-31 | $1.80 10-K · filed 2017-03-16 | |
| 2014-12-31 | $1.99 10-K · filed 2016-03-15 | |
| 2013-12-31 | $2.00 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |